Notably, SCENIC analysis revealed that there were mainly three kinds of TF expression with clusters 4 and 10 specifically expressing CEBPB and HOXA9; clusters 6 and 21 specifically expressing WDR5, EZH2 and MYC; cluster 9 specifically expressing TAL1 and RELA; and cluster 14 specifically expressing E2F427 and FOXM128 (Figure 4A–C and Figure S5B–E), suggesting that combined inhibitor usage may contribute to sarcoma therapy. Here, TF is linked to sarcoma.